Therefore, evaluation of PD-L1 expression on tumour cells may help to select patients who will benefit from immunotherapy providing an individualized therapeutic approach. Furthermore, PD-L1 expression is correlated with major driver and suppressor gene alterations and seems to predict survival in lung cancer patients (Jin et al. 2022). The gene discussed is CD274; the disease is neoplasm.